- Home
- CDTX
as 05-30-2025 4:00pm EST
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 333.3M | IPO Year: | 2015 |
| Target Price: | $41.17 | AVG Volume (30 days): | 157.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -20.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.14 - $28.42 | Next Earning Date: | 05-08-2025 |
| Revenue: | $302,000 | Revenue Growth: | -98.33% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cidara Therapeutics Inc. (CDTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ward Shane | CDTX | COO & CLO | Mar 11 '25 | Sell | $21.96 | 1,664 | $36,542.11 | 14,674 | |
| Tari Leslie | CDTX | CHIEF SCIENTIFIC OFFICER | Mar 11 '25 | Sell | $21.96 | 1,773 | $38,939.69 | 16,215 |
Latest Cidara Therapeutics Inc. News
CDTX Breaking Stock News: Dive into CDTX Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
RBC Raises Price Target on Cidara Therapeutics to $35 From $31, Keeps Outperform, Speculative Risk
GlobeNewswire
17 days ago
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
GlobeNewswire
19 days ago
Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
MT Newswires
23 days ago
RBC Cuts Price Target on Cidara Therapeutics to $31 From $34, Keeps Outperform, Speculative Risk
GuruFocus.com
23 days ago
Cidara Therapeutics Inc (CDTX) Q1 2025 Earnings Call Highlights: Promising Advances in ...
Associated Press Finance
23 days ago
Cidara Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
23 days ago
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
MT Newswires
a month ago
Cidara Therapeutics Names Nicole Davarpanah as Chief Medical Officer
Compare CDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDTX Cidara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.